Literature DB >> 12514458

The rationale and use of topiramate for treating neuropathic pain.

M S Chong1, Susan E Libretto.   

Abstract

OBJECTIVE: To outline the modes of action of topiramate and to examine the theoretical reasons as to why topiramate may alleviate neuropathic pain. Results of animal and human studies in the use of topiramate for treating pain are reviewed, together with case studies describing situations where topiramate was effective when other treatments have failed.
CONCLUSIONS: Topiramate acts on neuronal transmission in at least five ways: by modulating voltage-gated sodium ion channels, potentiating gamma-aminobutyric acid inhibition, blocking excitatory glutamate neurotransmission, modulating voltage-gated calcium ion channels, and by inhibiting carbonic anhydrase. This review suggests that there are good theoretical reasons for a trial of topiramate in patients with neuropathic pain where conventional medical treatments have failed. Although not currently licensed for treating pain, topiramate should be considered before invasive methods of pain relief are contemplated. Most of the side effects of topiramate are dose dependent, but by starting medication with a low dose (</=25 mg/d) that is gradually titrated upward, tolerance is much more easily achieved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12514458     DOI: 10.1097/00002508-200301000-00008

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  16 in total

Review 1.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

3.  Paroxysmal hemicrania responding to topiramate.

Authors:  A S Cohen; P J Goadsby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

4.  Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.

Authors:  Amanda Boyd; Carolina Casselini; Etta Vinik; Aaron Vinik
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

5.  Paroxysmal hemicrania responding to topiramate.

Authors:  A S Cohen; P J Goadsby
Journal:  BMJ Case Rep       Date:  2009-07-07

6.  Inhibition of carbonic anhydrase augments GABAA receptor-mediated analgesia via a spinal mechanism of action.

Authors:  Marina N Asiedu; Galo L Mejia; Christian A Hübner; Kai Kaila; Theodore J Price
Journal:  J Pain       Date:  2014-01-09       Impact factor: 5.820

Review 7.  Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain.

Authors:  Alan B Ettinger; Charles E Argoff
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

8.  Brain's compensatory response to drug-induced cognitive impairment.

Authors:  Immanuel Babu Henry Samuel; Christopher Barkley; Susan E Marino; Chao Wang; Sahng-Min Han; Angela K Birnbaum; Jean E Cibula; Mingzhou Ding
Journal:  J Clin Exp Neuropsychol       Date:  2018-05-02       Impact factor: 2.475

Review 9.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 10.  Pharmacological treatments for persistent non-malignant pain in older persons.

Authors:  Thorsten Nikolaus; Andrej Zeyfang
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.